Cargando…

Evaluating the Survival Benefit Following Ovarian Function Suppression in Premenopausal Patients with Hormone Receptor Positive Early Breast Cancer

There are divergent opinions regarding the use of ovarian function suppression or ablation (hereafter, OFS) in hormone receptor positive early breast cancer patients. In order to clarify the survival benefit of OFS, a meta-analysis was performed. The result is that use of OFS was more effective than...

Descripción completa

Detalles Bibliográficos
Autores principales:	Qiu, Lin, Fu, Fangmeng, Huang, Meng, Lin, Yuxiang, chen, Yazhen, Chen, Minyan, Wang, Chuan
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Nature Publishing Group 2016
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4882507/ https://www.ncbi.nlm.nih.gov/pubmed/27230285 http://dx.doi.org/10.1038/srep26627

Ejemplares similares

Evaluating the benefits and adverse effects of an enthracycline-taxane-capecitabine combined regimen in patients with early breast cancer
por: Zhang, Jiantang, et al.
Publicado: (2017)

Gonadotropin-Releasing Hormone Analog Cotreatment for the Preservation of Ovarian Function during Gonadotoxic Chemotherapy for Breast Cancer: A Meta-Analysis
por: Wang, Chuan, et al.
Publicado: (2013)

Associations of Two Common Genetic Variants with Breast Cancer Risk in a Chinese Population: A Stratified Interaction Analysis
por: Lin, Yuxiang, et al.
Publicado: (2014)

Genetic variants in long noncoding RNA H19 contribute to the risk of breast cancer in a southeast China Han population
por: Lin, Yuxiang, et al.
Publicado: (2017)

Adjuvant ovarian suppression for premenopausal hormone receptor-positive breast cancer: A network meta-analysis
por: Jiang, Mengjie, et al.
Publicado: (2021)

Association of Adjuvant Hormone Therapy Timing With Overall Survival Among Patients With Hormone Receptor–Positive Human Epidermal Growth Factor Receptor-2–Negative Early Breast Cancer Without Chemotherapy
por: Fu, Fangmeng, et al.
Publicado: (2022)

Ovarian Function Suppression With Luteinizing Hormone-Releasing Hormone Agonists for the Treatment of Hormone Receptor-Positive Early Breast Cancer in Premenopausal Women
por: Lu, Yen-Shen, et al.
Publicado: (2021)

Subtype-specific associations between breast cancer risk polymorphisms and the survival of early-stage breast cancer
por: Fu, Fangmeng, et al.
Publicado: (2018)

The precision relationships between eight GWAS-identified genetic variants and breast cancer in a Chinese population
por: Chen, Yazhen, et al.
Publicado: (2016)

Ovarian Function, Not Age, Predicts the Benefit from Ovarian Suppression or Ablation for Premenopausal Women with Breast Cancer
por: Xue, Cong, et al.
Publicado: (2016)

Impact of body mass index in therapeutic response for HER2 positive breast cancer treated with neoadjuvant targeted therapy: a multi-center study and meta-analysis
por: Chen, Lili, et al.
Publicado: (2023)

A nomogram prediction for the survival of patients with triple negative breast cancer
por: Lin, Yuxiang, et al.
Publicado: (2018)

Transcriptional Expressions of CXCL9/10/12/13 as Prognosis Factors in Breast Cancer
por: Li, Yan, et al.
Publicado: (2020)

HER2 copy number quantification in primary tumor and cell-free DNA provides additional prognostic information in HER2 positive early breast cancer
por: Chen, Xiaobin, et al.
Publicado: (2022)

Ovarian Ablation Using Goserelin Improves Survival of Premenopausal Patients with Stage II/III Hormone Receptor-Positive Breast Cancer without Chemotherapy-Induced Amenorrhea
por: Zhou, Juan, et al.
Publicado: (2015)

Role of Ovarian Function Suppression in Premenopausal Women with Early Breast Cancer
por: Park, Woo-Chan
Publicado: (2016)

Impact on disease-free survival of the duration of ovarian function suppression, as postoperative adjuvant therapy, in premenopausal women with hormone receptor-positive breast cancer: a retrospective single-institution study
por: Ozaki, Yukinori, et al.
Publicado: (2018)

Long-term comparisons of the efficacy, safety, and pregnancy outcomes of adjuvant tamoxifen plus ovarian function suppression in premenopausal Han and Zhuang Chinese patients with hormone receptor-positive early breast cancer
por: Tang, Shicong, et al.
Publicado: (2018)

Identification of potential key genes for HER-2 positive breast cancer based on bioinformatics analysis
por: Lin, Yuxiang, et al.
Publicado: (2020)

Dual HER2 Blockade versus a Single Agent in Trastuzumab-Containing Regimens for HER2-Positive Early Breast Cancer: A Systematic Review and Meta-Analysis of Randomized Controlled Trials
por: Yu, Liuwen, et al.
Publicado: (2020)

Ovarian reserve in premenopausal women with breast cancer
por: Zong, Xiangyun, et al.
Publicado: (2022)

The Impact of Young Age for Prognosis by Subtype in Women with Early Breast Cancer
por: Lian, Weibin, et al.
Publicado: (2017)

Myocardial Function in Premenopausal Women Treated With Ovarian Function Suppression and an Aromatase Inhibitor
por: Jordan, Jennifer H, et al.
Publicado: (2021)

Tamoxifen-induced ovarian hyperstimulation during premenopausal hormonal therapy for breast cancer in Japanese women
por: Yamazaki, Rena, et al.
Publicado: (2015)

Analysis of the benefit of gonadotropin-releasing hormone agonist treatment in premenopausal women undergoing hematopoietic cell transplantation
por: Han, Ruxue, et al.
Publicado: (2023)

Controversies in hormonal adjuvant therapy for premenopausal patients
por: Howell, A
Publicado: (2009)

Polymorphisms of long non-coding RNA HOTAIR with breast cancer susceptibility and clinical outcomes for a southeast Chinese Han population
por: Lin, Yuxiang, et al.
Publicado: (2017)

CTPS1 promotes malignant progression of triple-negative breast cancer with transcriptional activation by YBX1
por: Lin, Yuxiang, et al.
Publicado: (2022)

Thrombospondin 2 is a Functional Predictive and Prognostic Biomarker for Triple-Negative Breast Cancer Patients With Neoadjuvant Chemotherapy
por: Lin, Yuxiang, et al.
Publicado: (2022)

Diagnostic and predictive accuracy of anti-mullerian hormone for ovarian function after chemotherapy in premenopausal women with early breast cancer
por: Anderson, Richard A., et al.
Publicado: (2022)

Ovarian hormones and reproductive risk factors for breast cancer in premenopausal women: the Norwegian EBBA-I study
por: Iversen, A., et al.
Publicado: (2011)

YTHDF3 facilitates triple-negative breast cancer progression and metastasis by stabilizing ZEB1 mRNA in an m(6)A-dependent manner
por: Lin, Yuxiang, et al.
Publicado: (2022)

Effect of node status on breast cancer survival by subtype: a single-center retrospective cohort study
por: Lian, Weibin, et al.
Publicado: (2020)

Identifying Two Common Types of Breast Benign Diseases Based on Multiphoton Microscopy
por: Wu, Yan, et al.
Publicado: (2018)

LncRNA PCIR Is an Oncogenic Driver via Strengthen the Binding of TAB3 and PABPC4 in Triple Negative Breast Cancer
por: Guo, Wenhui, et al.
Publicado: (2021)

High Serum Estradiol Reduces Acute Hepatotoxicity Risk Induced by Epirubicin Plus Cyclophosphamide Chemotherapy in Premenopausal Women with Breast Cancer
por: Huang, Shunmin, et al.
Publicado: (2021)

Cigarette Smoking and Effects on Hormone Function in Premenopausal Women
por: Windham, Gayle C., et al.
Publicado: (2005)

Adjuvant hormonal therapy in premenopausal women with breast cancer
por: Smyth, Lillian, et al.
Publicado: (2015)

Meningiomas in Premenopausal Women: Role of the Hormone Related Conditions
por: Maiuri, Francesco, et al.
Publicado: (2020)

Ovarian function and ovarian blood supply following premenopausal abdominal hysterectomy
por: Abdelazim, Ibrahim A., et al.
Publicado: (2015)

Cannot write session to /tmp/vufind_sessions/sess_s7impl410b74bdo2ltue7ukkdm